{"id":250,"date":"2026-09-04T14:22:22","date_gmt":"2026-09-04T08:52:22","guid":{"rendered":"https:\/\/tadalafil-seller.com\/blog\/?p=250"},"modified":"2026-09-04T14:22:22","modified_gmt":"2026-09-04T08:52:22","slug":"who-gmp-tadalafil-api-manufacturers-and-suppliers","status":"publish","type":"post","link":"https:\/\/tadalafil-seller.com\/blog\/who-gmp-tadalafil-api-manufacturers-and-suppliers\/","title":{"rendered":"WHO-GMP Tadalafil API Manufacturers and Suppliers: A Sourcing Guide for US Buyers"},"content":{"rendered":"

Most tadalafil API sourcing decisions go wrong at the same point. A buyer receives a clean WHO-GMP certificate, a Certificate of Analysis showing 99.7 percent purity, and a competitive price per kilogram, and treats that package as sufficient evidence for a US filing. It is not. WHO-GMP and US cGMP are different frameworks issued by different authorities for different purposes, and the FDA assesses only one when it reviews an abbreviated new drug application.<\/p>\n

This guide sets out what the WHO-GMP designation actually covers, what a US buyer needs on top of it, and which documents to request before a purchase order is issued. It is written for formulation, quality, and procurement teams, not for patients.<\/p>\n

DIRECT ANSWER<\/span>A WHO-GMP tadalafil API manufacturer holds a GMP certificate issued under the WHO certification scheme, in India typically by a State Licensing Authority or CDSCO. For US-bound supply that certificate is a starting point, not a clearance. Buyers should additionally confirm an active US Type II Drug Master File available for reference, FDA establishment registration, and ICH Q7 compliance.<\/div>\n

What does “WHO-GMP tadalafil API” actually mean?<\/h2>\n

WHO-GMP refers to the good manufacturing practice standard described in WHO Technical Report Series 986, Annex 2. It is an international reference framework. The World Health Organization does not itself inspect factories or issue certificates to individual companies. National regulators do that, and they issue the certificate under the WHO certification scheme.<\/p>\n

In India, that means a State Licensing Authority or CDSCO inspects the site and issues a WHO-GMP certificate, usually alongside a Certificate of Pharmaceutical Product (COPP). Both documents are named for a specific site and a specific product list. A WHO-GMP certificate that covers a different product, or a different block at the same address, does not cover your tadalafil API.<\/p>\n

WHO-GMP versus India’s revised Schedule M<\/h3>\n

Schedule M of the Drugs and Cosmetics Rules is India’s domestic statutory GMP requirement. The revised Schedule M, notified in December 2023, moved Indian GMP substantially closer to WHO-GMP by adding formal pharmaceutical quality system, product quality review, quality risk management, validation lifecycle and computerised systems requirements. Large manufacturers came into scope from mid-2024, with a phased extension for smaller units.<\/p>\n

The practical consequence for buyers: a site that was WHO-GMP certified before this transition may have been recertified under materially different expectations since. Ask for the certificate issue date and the most recent inspection date, not just the certificate.<\/p>\n

\"WHO-GMP
WHO-GMP versus India’s revised Schedule M<\/figcaption><\/figure>\n

WHO-GMP versus US cGMP, and why the difference matters<\/h3>\n
\n

Common misconception<\/span><\/p>\n

The FDA does not “approve” an API on its own, and it does not recognise a WHO-GMP certificate as evidence of US cGMP compliance. An API becomes usable in a US-marketed drug product only through an approved application (NDA or ANDA) for the finished product, which references the API’s manufacturing data. Supplier directories that describe an API as “FDA approved” are using the term loosely.<\/p>\n<\/div>\n

For US supply, the operative GMP expectation for an API manufacturer is ICH Q7, adopted by the FDA as guidance for industry. A site can hold a valid WHO-GMP certificate and still not be ready for an FDA pre-approval inspection. Treat the two as separate qualification tracks that happen to overlap.<\/p>\n

What US buyers must verify beyond the WHO-GMP certificate<\/h2>\n

1. An active US Type II DMF, available for reference.<\/strong> A Type II Drug Master File covers the API and its intermediates. Filing one is voluntary, and a DMF is never itself approved or rejected. Its contents are assessed only when an application references it. Under GDUFA, a Type II API DMF must have paid its fee and passed a completeness assessment before an ANDA can reference it. If it has not, the FDA will refuse to receive the referencing ANDA. Ask the supplier for the DMF number and confirm it appears on the FDA’s published list of Type II DMFs available for reference. [Source: FDA, Types of Drug Master Files; FDA, Completeness Assessments for Type II API DMFs Under GDUFA]<\/p>\n

2. A Letter of Authorization.<\/strong> The DMF holder must issue an LoA naming your application before the FDA will look at the file on your behalf. Confirm the supplier will issue one, in writing, before you commit.<\/p>\n

3. FDA establishment registration.<\/strong> Foreign sites shipping drug substance to the US register with the FDA and receive an FEI number. Ask for it and verify the registered address matches the manufacturing address on the CoA, not the trading office address.<\/p>\n

4. Inspection history.<\/strong> Request the date and outcome of the last regulatory inspection, and ask directly whether the site has received an FDA Form 483 or warning letter. A supplier that declines to answer has told you something.<\/p>\n

5. Patent and freedom-to-operate position.<\/strong> Tadalafil’s principal US patents have expired and generic competition is active, but formulation, polymorph and use patents can persist independently of the compound patent. Several API directories carry a standing note that patented products are offered for research and development purposes only. Verify your own position; do not rely on a supplier’s disclaimer.<\/p>\n

Which documents should you request before ordering?<\/h2>\n

Send this list as a single request at first contact. Response speed and completeness are themselves a qualification signal.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Document<\/th>\nWhat it tells you<\/th>\nPriority<\/th>\n<\/tr>\n
Certificate of Analysis (batch specific)<\/td>\nAssay, related substances, residual solvents, water content, heavy metals, against a stated pharmacopeial monograph<\/td>\nEssential<\/td>\n<\/tr>\n
WHO-GMP certificate and COPP<\/td>\nSite and product scope, issuing authority, validity dates<\/td>\nEssential<\/td>\n<\/tr>\n
US Type II DMF number and LoA commitment<\/td>\nWhether the API can support a US ANDA at all<\/td>\nEssential for US<\/td>\n<\/tr>\n
CEP \/ COS<\/td>\nEDQM assessment against the European Pharmacopoeia monograph, relevant for EU-bound supply<\/td>\nMarket dependent<\/td>\n<\/tr>\n
Stability data (ICH Q1A)<\/td>\nRetest period, storage conditions, degradation profile in your climatic zone<\/td>\nEssential<\/td>\n<\/tr>\n
Impurity profile and method validation<\/td>\nIdentified, unidentified and total impurities; whether analytical methods are validated to ICH Q2<\/td>\nEssential<\/td>\n<\/tr>\n
Nitrosamine risk assessment<\/td>\nWhether the route of synthesis has been assessed for nitrosamine formation<\/td>\nIncreasingly expected<\/td>\n<\/tr>\n
MSDS, BSE\/TSE and elemental impurity statements<\/td>\nHandling, animal-origin freedom, ICH Q3D position<\/td>\nStandard<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Manufacturer, supplier, exporter or distributor?<\/h2>\n

B2B marketplaces routinely list these four roles under a single “supplier” label, and the distinction is the one buyers most often skip. The party selling the material may not be the party that manufactured, released, registered or exported it.<\/p>\n\n\n\n\n\n\n\n
Role<\/th>\nWhat they control<\/th>\nThe question to ask<\/th>\n<\/tr>\n
API manufacturer<\/td>\nRoute of synthesis, GMP site, batch release, DMF holding<\/td>\nDo you hold the DMF, or does someone else?<\/td>\n<\/tr>\n
Exporter<\/td>\nShipping documentation, customs, export licensing<\/td>\nWhich manufacturing site appears on the CoA?<\/td>\n<\/tr>\n
Distributor \/ trader<\/td>\nStock, repacking, onward sale<\/td>\nHas this material been repacked, and under whose GMP?<\/td>\n<\/tr>\n
Intermediate supplier<\/td>\nUpstream starting materials, not the finished API<\/td>\nAt which step does GMP coverage begin?<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Repacking is the quiet risk. If a trader has resized drums, the chain of custody and the original manufacturer’s retest period may both be compromised. Publicly available listings show tadalafil API production concentrated in India, China and Poland, with both the originator and multiple secondary packagers present in the market, which makes supply-chain traceability a live question rather than a formality.<\/p>\n

Tadalafil API specification attributes worth scrutinising<\/h2>\n

Tadalafil is a poorly water-soluble compound, so attributes that would be secondary for a freely soluble API become primary here.<\/p>\n